Literature DB >> 17894848

The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.

Masahide Hamaguchi1, Takao Kojima, Yoshito Itoh, Yuichi Harano, Kota Fujii, Tomoaki Nakajima, Takahiro Kato, Noriyuki Takeda, Junichi Okuda, Kazunori Ida, Yutaka Kawahito, Toshikazu Yoshikawa, Takeshi Okanoue.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is closely associated with the metabolic syndrome. AIM: We evaluated the association among the metabolic syndrome, visceral fat accumulation, and the severity of fatty liver with a new scoring system of ultrasonographic findings in apparently healthy Japanese adults.
METHODS: Subjects consisted of 94 patients who received liver biopsy and 4,826 participants who were selected from the general population. Two hepatologists scored the ultrasonographic findings from 0 to 6 points. We calculated Cohen's kappa of within-observer reliability and between-observer reliability. We evaluated the predictive value of the score by the area under a conventional receiver operating characteristic curve (AUC).
RESULTS: Within-observer reliability was 0.95 (95% CI 0.93-0.97, P<0.001) and between-observer reliability was 0.95 (95% CI 0.93-0.97, P<0.001). The AUC to diagnose NAFLD was 0.980. The sensitivity was 91.7% (95% CI 87.0-95.1, P<0.001) and the specificity was 100% (95% CI 95.4-100.0, P<0.001). The AUC to diagnose visceral obesity was 0.821. The sensitivity was 68.3% (95% CI 51.9-81.9, P=0.028) and the specificity was 95.1% (95% CI 86.3-99.0, P<0.001). Adjusted odds ratio of the score for the metabolic syndrome was 1.37 (95% CI 1.26-1.49, P<0.001).
CONCLUSIONS: The scoring system with abdominal ultrasonography could provide accurate information about hepatic steatosis, visceral obesity, and the metabolic syndrome in apparently healthy people who do not consume alcohol.

Entities:  

Mesh:

Year:  2007        PMID: 17894848     DOI: 10.1111/j.1572-0241.2007.01526.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  240 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  Biochemical determination of lipid content in hepatic steatosis by the Soxtec method.

Authors:  Elizabeth Hijona; Lander Hijona; Mikel Larzabal; Cristina Sarasqueta; Pablo Aldazabal; Juan Arenas; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

3.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

4.  Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.

Authors:  Jeffrey C Sirota; Kim McFann; Giovanni Targher; Richard J Johnson; Michel Chonchol; Diana I Jalal
Journal:  Metabolism       Date:  2012-10-02       Impact factor: 8.694

5.  Risk of Colorectal Neoplasia According to Fatty Liver Severity and Presence of Gall Bladder Polyps.

Authors:  Taeyoung Lee; Kyung Eun Yun; Yoosoo Chang; Seungho Ryu; Dong Il Park; Kyuyong Choi; Yoon Suk Jung
Journal:  Dig Dis Sci       Date:  2015-09-18       Impact factor: 3.199

6.  Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.

Authors:  O Başar; E Akbal; S Köklü; Y Tuna; E Koçak; N Başar; D Tok; H Erbiş; M Senes
Journal:  Herz       Date:  2013-01-18       Impact factor: 1.443

Review 7.  Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease.

Authors:  Mustafa Koplay; Mesut Sivri; Hasan Erdogan; Alaaddin Nayman
Journal:  World J Hepatol       Date:  2015-04-18

8.  HBV genotype C is independently associated with cirrhosis in community-based population.

Authors:  Jian-Hua Yin; Jun Zhao; Hong-Wei Zhang; Jia-Xin Xie; Wei-Ping Li; Guo-Zhang Xu; Jie Shen; Hong-Jun Dong; Jun Zhang; Lin Wang; Jian-Kang Han; Hong-Yang Wang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

9.  Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease.

Authors:  Licia Polimeni; Daniele Pastori; Francesco Baratta; Giulia Tozzi; Marta Novo; Roberto Vicinanza; Giovanni Troisi; Gaetano Pannitteri; Fabrizio Ceci; Laura Scardella; Francesco Violi; Francesco Angelico; Maria Del Ben
Journal:  Intern Emerg Med       Date:  2017-09-12       Impact factor: 3.397

10.  The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.

Authors:  A Campanati; G Ganzetti; A Di Sario; A Damiani; L Sandroni; L Rosa; A Benedetti; A Offidani
Journal:  J Gastroenterol       Date:  2012-10-13       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.